The questions that stand between us and a cure
X
of the most pressing open questions in medicine, across seven areas and a whole human lifetime.
X
Projects
Oncology and Immunotherapy
Which patients respond to the newest cancer drugs, which targets to hit next, and why tumors resist.
Which ADC mono- and multi-specifics can target all malignant cancer subclones in a the largest proportion of patients in a ovarian cancer?
Data
Knowledge
Analysis
Validation
Discovery
Which ADC mono- and multi-specifics can target all malignant cancer subclones in a the largest proportion of patients in bladder cancer?
Data
Knowledge
Analysis
Validation
Discovery
Which ADC mono- and multi-specifics can target all malignant cancer subclones in a the largest proportion of patients in a given cancer?
Data
Knowledge
Analysis
Validation
Discovery
Which drugs combined to KRAS inhibitors can increase response in cancer?
Data
Knowledge
Analysis
Validation
Discovery
Which unrecognized pathways drive treatment resistance in glioblastoma, and which can be targeted?
Data
Knowledge
Analysis
Validation
Discovery
What distinguishes exceptional responders to TROP2 antibody–drug conjugates in non-small cell lung cancer?
Data
Knowledge
Analysis
Validation
Discovery
Which biomarkers predict response, resistance and toxicity to enfortumab vedotin plus pembrolizumab in bladder cancer?
Data
Knowledge
Analysis
Validation
Discovery
Which bladder cancer patients can safely avoid radical cystectomy without compromising survival?
Data
Knowledge
Analysis
Validation
Discovery
Which DLBCL patients can be treated with immunotherapy and targeted therapy instead of chemotherapy?
Data
Knowledge
Analysis
Validation
Discovery
Join us
Be part of the vision
For frontier labs and investors who want to join us in this mission.
